medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2023, Number 6

<< Back Next >>

Salud Mental 2023; 46 (6)

Is there interest of Mexican adults in being prepared should they develop Alzheimer’s or other dementia?

Marván ML, Castillo-López RL, Onofre-Corredor D, Vargas-Huicochea I, Álvarez-del-Río A

Language: English
References: 39
Page: 307-316
PDF size: 212.74 Kb.


ABSTRACT

Introduction. Alzheimer's disease, as well as other dementias, cause a progressive deterioration of cognitive functions, preventing patients from making decisions and having control over themselves in an advanced stage of the disease. Objective. To explore some expectations, wishes and preferences in a sample of mature adults should they develop Alzheimer or other dementia. Method. We surveyed 368 mature Mexican adults without dementia using a large survey created by the authors and used in a previous study; data were collected in some public places where mature people were invited to participate. The survey was completed from July 2019 to August 2020. Results. Although most participants had considered they might suffer from dementia in the future, less than half had communicated their wishes to their relatives about future medical treatments in case they could no longer decide for themselves; very few had prepared a written advance directive. Most participants agreed that patients should know their initial diagnosis, mainly to be able to prepare themselves. The main reason given by those who would prefer to hide the diagnosis was to avoid suffering. Discussion and conclusion. Our results highlight the need for health professionals to promote discussion with people about the possibility of suffering from dementia, as well as the importance of making decisions in advance, and letting their relatives know about them.


REFERENCES

  1. Álvarez-del Río, A., & Marván, M. L. (2021). Dilemas éticos ante la Posibilidad dePadecer la Enfermedad de Alzheimer u otras Demencias. Estudio Exploratorio.Gaceta Médica de México, 157(4), 418-424. doi: 10.24875/gmm.20000848

  2. Alzheimer’s Association. (2023). Lecanemab Approved for Treatment of EarlyAlzheimer’s Disease. Alzheimer’s Association. Retrieved from https://www.alz.org/alzheimers-dementia/treatments/lecanemab-leqembi

  3. AMGEN. (2018). World’s Largest Alzheimer’s Survey Reveals Most Adults Believe aCure Will be Developed in Their Lifetime. Retrieved from https://www.multivu.com/players/English/8004557-amgen-global-alzheimers-disease-awarenesssurvey/(September 17, 2018)

  4. Brewer, C. (2019). O, Let Me Not Get Alzheimer’s Sweet Heaven. SkyscraperPublications Limited.

  5. Briggs, R., McHale, C., Fitzhenry, D., O’Neill, D., & Kennelly, S. P. (2018). Dementia,Disclosing the Diagnosis. QJM: An International Journal of Medicine, 111(4),215-216. doi: 10.1093/qjmed/hcx181

  6. Brinkman-Stoppelenburg, A., Evenblij, K., Pasman, H. R., van Delden, J. J.,Onwuteaka-Philipsen, B. D., & van der Heide, A. (2020). Physicians’ and PublicAttitudes Toward Euthanasia in People with Advanced Dementia. Journal of theAmerican Geriatrics Society, 68(10), 2319-2328. doi: 10.1111/jgs.16692

  7. Carpenter, B., & Dave, J. (2004). Disclosing a Dementia Diagnosis: A Review ofOpinion and Practice, and a Proposed Research Agenda. The Gerontologist,44(2), 149-158. doi: 10.1093/geront/44.2.149

  8. Clarke, G., Fistein, E., Holland, A., Barclay, M., Theimann, P., & Barclay, S. (2017).Preferences for care towards the end of life when decision-making capacitymay be impaired: A large scale cross-sectional survey of public attitudes inGreat Britain and the United States. PLoS ONE, 12(4), e0172104. doi: 10.1371/journal.pone.0172104

  9. Cohen, J., Marcoux, I., Bilsen, J., Deboosere, P., van der Wal, G., & Deliens, L.(2006). European Public Acceptance of Euthanasia: Socio-Demographic andCultural Factors Associated with the Acceptance of Euthanasia in 33 EuropeanCountries. Social Science & Medicine, 63(3), 743-756. doi: 10.1016/j.socscimed.2006.01.026

  10. Donnelley, P. (2014). We Fear Dementia More Than Cancer: Two Thirds of Over-50sFear They Will Get Brain Condition. Daily Mail Online. Retrieved from https://www.dailymail.co.uk/health/article-2715049/We-fear-dementia-cancer-Twothirds-50s-fear-brain-condition.html (August 14, 2014)

  11. D’Hyver, C. (2018). Ética y Alzheimer. Es un Dilema. In O. Rivero-Serrano (Ed.).Reflexiones Sobre Dilemas Éticos en la Práctica Médica, Tomo I (pp. 59-72).Universidad Nacional Autónoma de México.

  12. González-Huerta, I., Gutiérrez-Soriano, J., & Álvarez-del-Río, A. (2017). Decisionesmédicas sobre el final de la vida en pacientes con enfermedad de Alzheimer.Fontamara.

  13. Gutiérrez-Robledo, L. M., & Arrieta-Cruz, I. (2015). Demencias en México: LaNecesidad de un Plan de Acción. Gaceta Médica de México, 151(5), 667-673.

  14. Hernández, A., & Torres, S. (2017). La Necesidad de Cuidados del Paciente conAlzheimer y la Respuesta Social Organizada. In L. M. Gutiérrez-Robledo, M.C. García-Peña, P. A. Roa-Rojas, & A. Martínez-Ruiz (Eds.). La Enfermedad deAlzheimer y otras demencias, como problema nacional de salud (pp. 97-100).Intersistemas/CONACYT

  15. Hickman, R. A., Faustin, A., & Wisniewski, T. (2016). Alzheimer Disease andIts Growing Epidemic: Risk Factors, Biomarkers, and the Urgent Needfor Therapeutics. Neurologic Clinics, 34(4), 941-953. doi: 10.1016/j.ncl.2016.06.009

  16. Hodes, R. (2023). Anouncements: NIA statement on report of lecanemab reducingcognitive decline in Alzheimer’s clinical trial. National Institute on Aging.Retrieved from https://www.nia.nih.gov/news/nia-statement-report-lecanemabreducing-cognitive-decline-alzheimers-clinical-trial (06 Enero, 2023)

  17. Holroyd, S., Turnbull, Q., & Wolf, A. M. (2002). What are Patients and TheirFamilies Told About the Diagnosis of Dementia? Results of a Family Survey.International Journal of Geriatric Psychiatry, 17(3), 218-221. doi: 10.1002/gps.552

  18. Instituto Nacional de Estadística, Geografía e Informática [INEGI]. (2020).Estadísticas a Propósito del Día Mundial de la Población (11 de Julio) DatosNacionales. Comunicado de Prensa Num. 302/20, 9 de Julio de 2020. Retrievedfrom https://www.inegi.org.mx/contenidos/saladeprensa/aproposito/2020/Poblacion2020_Nal.pdf

  19. Irish Hospice Foundation [IHF]. (2016). IHF Launch Seven Guidance Documentsto Improve Palliative Care for People with Dementia. Retrieved from https://hospicefoundation.ie/other/ihf-launch-seven-guidance-documents-improvepalliative-care-people-dementia/

  20. Lopez, R. P., Rose, K. M., Kenney, L., Sanborn, V., & Davis, J. D. (2020). ManagingShame: A Grounded Theory of How Stigma Manifests in Families Living WithDementia. Journal of the American Psychiatric Nurses Association, 26(2), 181-188. doi: 10.1177/1078390319832965

  21. Low, L. F., McGrath, M., Swaffer, K., & Brodaty, H. (2019). Communicating aDiagnosis of Dementia: A Systematic Mixed Studies Review of Attitudesand Practices of Health Practitioners. Dementia, 18(7-8), 2856-2905. doi:10.1177/1471301218761911

  22. Mahieux, F., Herr, M., & Ankri, J. (2018). What Are the Preferences of PatientsAttending a Memory Clinic for Disclosure of Alzheimer՚s Disease? RevueNeurologique, 174(7-8), 564-570. doi: 10.1016/j.neurol.2017.10.016

  23. Mastwyk, M., Dow, B., Ellis, K. A., & Ames, D. (2016). Why Attend a MemoryClinic? What do Patients and Their Families Want and/or Expect? AustralasianJournal on Ageing, 35(3), 220-224. doi: 10.1111/ajag.12257

  24. Pan American Health Organization [PAHO]. (2017). Life Expectancy in the AmericasIncreases to 75 Years. Retrieved from https://www3.paho.org/hq/index.php?option=com_content&view=article&id=13722:life-expectancy-in-theamericas-increases-to-75-years&Itemid=1926&lang=en (September 26, 2017)

  25. Piers, R., Albers, G., Gilissen, J., De Lepeleire, J., Steyaert, J., Van Mechelen,W., ... Van den Block, L. (2018). Advance Care Planning in Dementia:Recommendations for Healthcare Professionals. BMC Palliative Care, 17(1),88. doi: 10.1186/s12904-018-0332-2

  26. Porteri, C. (2018). Advance Directives as a Tool to Respect Patients’ Values andPreferences: Discussion on the Case of Alzheimer՚s Disease. BMC MedicalEthics, 19(1), 9. doi: 10.1186/s12910-018-0249-6

  27. Reardon, S. (2023). FDA approves Alzheimer’s drug lecanemab amid safetyconcerns. Nature, 613(7943), 227-228. doi: 10.1038/d41586-023-00030-3

  28. Reitz, C., & Mayeux, R. (2014). Alzheimer Disease: Epidemiology, DiagnosticCriteria, Risk Factors and Biomarkers. Biochemical Pharmacology, 88(4), 640-651. doi: 10.1016/j.bcp.2013.12.024

  29. Steinbock, B., & Menzel, P. T. (2018). Advance Directives for Refusing Life-Sustaining Treatment in Dementia. Hasting Center Report, 48(S3). S75-S79.doi: 10.1002/hast.919

  30. Tarawneh, R., & Holtzman, D. M. (2012). The Clinical Problem of SymptomaticAlzheimer Disease and Mild Cognitive Impairment. Cold Spring HarborPerspectives in Medicine, 2(5), a006148. doi: 10.1101/cshperspect.a006148

  31. The Lancet. (2022). Lecanemab for Alzheimer’s disease: tempering hype and hope.The Lancet, 400(10367), 1899. doi: 10.1016/S0140-6736(22)02480-1

  32. van Wijmen, M., Pasman, R., Widdershoven, G., & Onwuteaka-Philipsen, B. (2015).Continuing or forgoing treatment at the end of life? Preferences of the generalpublic and people with an advance directive. Journal of Medical Ethics, 41(8),599-606. doi: 10.1136/medethics-2013-101544

  33. Velázquez López, G. (2018). Síndromes demenciales. In J. R. de la Fuente, G. Heinze(Eds.). Salud mental y medicina psicológica (pp. 261-283). McGraw-Hill.

  34. Volhard, T., Jessen, F., Kleineidam, L., Wolfsgruber, S., Lanzerath, D., Wagner, M.,& Maier, W. (2018). Advance Directives for Future Dementia Can Be Modifiedby a Brief Video Presentation on Dementia Care: An Experimental Study. PloSOne, 13(5), e0197229. doi: 10.1371/journal.pone.0197229

  35. Volicer, L. (2016). Fear of Dementia. Journal of the American Medical DirectorsAssociation, 17(10), 875-878. doi: 10.1016/j.jamda.2016.06.022

  36. Williams, N., Dunford, C., Knowles, A., & Warner, J. (2007). Public attitudes tolife-sustaining treatments and euthanasia in dementia. International Journal ofGeriatric Psychiatry, 22(12), 1229-1234. doi: 10.1002/gps.1819

  37. World Health Organization [WHO]. (2021). Dementia. Retrieved from https://www.who.int/news-room/fact-sheets/detail/dementia (September 2, 2021)

  38. Yadav, K. N., Gabler, N. B., Cooney, E., Kent, S., Kim, J., Herbst, N., … Courtright,K. R. (2017). Approximately One In Three US Adults Completes Any Type OfAdvance Directive For End-Of-Life Care. Health Affairs, 36(7), 1244-1251.doi: 10.1377/hlthaff.2017.0175

  39. Yates, J., Stanyon, M., Samra, R., & Clare, L. (2021). Challenges in Disclosingand Receiving a Diagnosis of Dementia: A Systematic Review of Practicefrom the Perspectives of People With Dementia, Carers, And HealthcareProfessionals. International Psychogeriatrics, 33(11), 1161-1192. doi: 10.1017/S1041610221000119




2020     |     www.medigraphic.com